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PROCESS FOR ENHANCING THE ACTIVITY

peptide coupling reaction is affected in solution in DMF and
the product of the reaction is isolated by evaporation of the
DMF or by precipitation by addition of a second solvent
Which renders the somatostatin insoluble. Then, the obtained

OF AMYLOID [3 PEPTIDES
This invention Was made With Government support

crude peptide is puri?ed by solid phase Washings With the

under Grant No. AG-10836 awarded by the National Insti
tute of Health. The Government may have certain rights in
this invention.

aid of suitable solvents Which dissolve the impurities.
U.S. Pat. No. 5,250,660 to Shuman relates to a process for

the puri?cation of peptides comprising chromatographing
the impure salt of certain tripeptides via reversed phase high

FIELD OF THE INVENTION

This invention relates to a novel process for enhancing

10

activity of an oligopeptide or polypeptide comprising the
steps of: providing an oligopeptide or polypeptide, dissolv
ing the oligopeptide or polypeptide in an organic solvent,

form of the tripeptide at a pH betWeen about 2 and about 3.
15

invention also provides novel oligopeptides and polypep
tides enhanced by the process according the invention.
20

proteolytic product of amyloid precursor protein. Amyloid [3
peptide comprises the 28 amino acids immediately amino
terminal to the single transmembrane domain of the precur
sor plus the ?rst 11—15 residues of that domain. The amyloid

from a primary dextran sulphate-sepharose af?nity step Were
directly applied to a mAbP2-1 monoclonal antibody immu

domains. Amyloid plaques, a brain lesion diagnostic of

AlZheimer’s disease, are composed primarily of amyloid [3
peptide. Synthetic amyloid [3 peptides are toxic to central
this neurotoxicity is poorly understood, there have been

noaf?nity column. After Washing, apparently homogenous
30

duction enhanced by the peptide.
Various processes for preparing and purifying biological

Which Will recogniZe antigenic determinants of the polypep
35

solubiliZed form and an agent capable of rupturing atomic

forces Within the molecule, and (2) contacting the protein
With the atomic forces rupturing agent in an amount suf?
cient to alloW the protein to convert to physiologically active

40

screening for AlZheimer’s disease, comprising the steps of:
obtaining a skin tissue biopsy sample from a patient
45

US. Pat. No. 5,144,006 to Tam relates to a method for the

[3-amyloid protein, from the biopsy sample, and thereby
obtaining an extract sample; optionally additionally
solubiliZing the [3-amyloid protein or the [3-amyloid

precursor protein fragment comprising [3-amyloid pro

replaced With a reaction inert substituent such as hydroxy or

halogen. These include symmetrical and non-symmetrical
55

containing four or ?ve carbon atoms.
US. Pat. No. 4,530,784 to Rosenberg relates to a method
of extracting a biologically active factor that restores contact

inhibition of groWth to malignant cells in mammals by

suspected of having AlZheimer’s disease; performing
an extraction suitable for extracting [3-amyloid protein,
or a [3-amyloid precursor protein fragment comprising

oxidative folding of a peptide or protein substrate containing
reactive sulfhydryl groups to form disul?de rings on bridges
by reacting the substrate in an aqueous media With DMSO
or other hydrocarbon sul?tes. Other hydrocarbon sul?tes
include substituted hydrocarbons in Which hydrogen is
dialkyl sulfoxide containing up to six carbon atoms and
further compounds in Which the sulphur atom and the carbon
atoms to Which it is joined form a cyclic alkylene sulfoxide

tide or homologous polypeptides in tissues or body ?uids
and Which may be used in a speci?c immunologic diagnostic
test for AlZheimer’s disease. Moreover, the polypeptide can
be used to produce a nucleotide probe Which can hybridiZe
With the gene Which codes for this or a homologous polypep
tide. Such a probe can also be utiliZed in a speci?c diagnostic
test for the disease.
U.S. Pat. No. 5,262,332 to Selkoe relates to a method for

form. The patent discloses that protein aggregates Which
may be recovered are selected from protein precipitates

including inclusion bodies and cytoplasmic aggregates.

PN-2 Was eluted With loW pH buffer. The overall activity
yield from numerous puri?cations Was betWeen 70—85%.
U.S. Pat. No. 4,666,829 to Glenner et al. discloses a novel
polypeptide Which is used as a marker for AlZheimer’s
disease. The polypeptide can be used to obtain antibodies

reports that the neurotoxicity results from free radical pro

materials are knoWn in the art. For example, US. Pat. No.
4,966,963 to Patroni discloses a method for the preparation
of a protein in a biologically active or native form, Which
method includes (1) providing a source of protein in a

the puri?cation, detection and methods of use of protease
nexin-2 (PN-2) Which is believed to be derived from the
[3-amyloid precursor protein. The patent discloses a method
for purifying PN-2 employing a monoclonal antibody pro
duced by Hybridoma Cell Line mAbP2-1 in an immunoaf

?nity step. In this method, pooled PN-2 containing fractions

[3 peptide contains both hydrophobic and hydrophilic

nervous system neurons in vitro. While the mechanism for

FolloWing the collection of the salt of the tripeptide in the
eluate, the pH of the eluate is adjusted With Water insoluble
resin in basic form to betWeen about pH 4 to about pH 6,
?ltering the resin and isolating the pure salt by removing the
Water from the ?ltrate.
U.S. Pat. No. 5,213,962 to Van Nostrand et al. relates to

BACKGROUND

Amyloid [3 peptide is a 39-43 residue peptide Which is a

ent of about 2% to about 40% acetonitrile in an aqueous

phase containing an inorganic acid corresponding to the salt

heating, removing the solvent, and recovering an oligopep
tide or polypeptide With enhanced activity. The present

performance liquid chromatography by employing a gradi

tein present in the extract sample, and thereby obtain
ing a solution sample;
contacting the extract sample or the solution sample With
a quantity of antibodies speci?c to [3-amyloid protein or
to a precursor protein fragment comprising [3-amyloid
protein or to a peptide fragment of [3-amyloid protein of
at least about eight amino acids suf?cient to alloW

detection of said protein, protein fragment or peptide
60

fragment; and, detecting the speci?c binding reaction in

mixing a media conditioned by groWth of a contact inhibited

the extract or solution sample betWeen the antibodies

cell culture together With a volatile non-denaturing precipi
tating agent. The precipitate formed by this reaction is
separated from the mixture and extracted With a biologically

protein fragment comprising [3-amyloid protein

acceptable ionic buffering agent.
US. Pat. No. 4,337,194 to DiaZ et al. relates to a process

for the preparation of somatostatin Wherein a step-Wise

and the [3-amyloid protein or the [3-amyloid precursor

65

Wherein the presence of said binding reaction is indica
tive of AlZheimer’s disease.

Many oligopeptides and polypeptides are necessary
research tools for the study of pathWays underlying various

5,840,838
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diseases. For example, synthetic amyloid B peptides are a
necessary research tool for the study of the neurotoxicity
that results from free radical production enhanced by the

heating, removing the solvent, and recovering an oligopep
tide or polypeptide With enhanced activity. The invention is
based, in part, on the inventors’ surprising and unexpected
discovery that the process increases the chemical reactivity,

amyloid [3 peptide. Unfortunately, some oligopeptides and
polypeptides such as synthetic amyloid [3 peptides demon

biological functioning and aggregational characteristics of
oligopeptides and polypeptides.

strate signi?cant lot-to-lot variations in toxicity Which is not
attributed to contaminants or peptide impurities and Which
decreases their commercial value. More speci?cally, peptide
reactivity greatly varies betWeen synthetic lots due to struc
tural factors. This variation is a major impediment because
research cannot be accurately reproduced. None of the
above-described processes and methods adequately address
this problem. Thus, a long-felt need in the art exists for a
process for treating oligopeptides and polypeptides such as

10

logically active polypeptides and peptides include groWth

synthetic amyloid B peptides, and other synthetic peptides,

15

beta peptides, substance P peptide, catalytic antibodies,
enZymes, and fragments thereof. Examples of synthetic
oligopeptides and polypeptides corresponding to the amy
loid beta peptide include A[3(1-15) (SEQ ID NO:1), A[3(1

The present invention is particularly applicable to bio
logically active structure dependent oligopeptides and
polypeptides. These oligopeptides and polypeptides may be
puri?ed or unpuri?ed, and natural or synthetic. These bio

hormones, interferons, immunogens, lymphokines, amyloid

to create more uniformity in research applications. The
present invention addresses this need.
SUMMARY OF THE INVENTION

It is accordingly one object of the present invention to
provide a novel process for enhancing activity of an oli

20

The oligopeptide or polypeptide may be dissolved in any

suitable structure forming organic solvent, that is, solvents
Which modulate protein secondary and higher order struc

gopeptide or polypeptide comprising the steps of: providing
an oligopeptide or polypeptide, dissolving the oligopeptide
or polypeptide in an organic solvent, heating, removing the
solvent, and recovering an oligopeptide or polypeptide With

28) (SEQ ID NO:2), A[3(1-30) (SEQ ID NO:3), A[3(1-33)
(SEQ ID NO:4),A[3(25-35) (SEQ ID NO:5),A[3(1-36) (SEQ
ID NO:6), A[3(1-39) (SEQ ID NO:7), A[3(1-40) (SEQ ID
NO:8), A[3(1-42) (SEQ ID NO:9), A[3(1-47) (SEQ ID
NO:10), and A[3(1-52) (SEQ ID NO:11).

ture. Suitable structure forming solvents include
25

tri?uoroethanol,
dimethyl
sulfoxide,
hexa?uorocyclohexane, morpholino-propanesulfonic acid,

enhanced activity.

dimethylformamide, and acetonitrile. In a preferred

Another object of the invention is to provide a novel
process for enhancing activity of an oligopeptide or

With the solvent.

polypeptide Wherein there is negligible sample loss.

embodiment, the oligopeptide or polypeptide is pre-treated
30

A further object of the present invention is to provide
novel oligopeptides and polypeptides enhanced by the pro
cess according the invention.
The above and other objects of the invention Will become
readily apparent to those of skill in the relevant art from the

by any suitable means, for example, by thoroughly degas

sing by N2 sparge.
35

folloWing detailed description, Wherein only the preferred
embodiments of the invention are shoWn and described,

simply by Way of illustration of the best mode of carrying
out the invention. As is readily recogniZed, the invention is
capable of modi?cations Within the skill of the relevant art
Without departing from the spirit and scope of the invention.

40

45

50

immediately. The solvent may be removed by any appro
priate method, so long as the method is suitable for the
solvent and oligopeptide or polypeptide. Preferred methods

for removing the solvent include evaporative deposition, for

in parallel With, and using aliquots of the sample peptide

example, under a stream of N2 gas, and lyophiliZation. The
duration of the solvent removal step is (rapid) about 5

preparations;
FIGS. 4A—4D shoW electron micrographs of A[3(1-40)
(SEQ ID NO:8) before and after TFE-SARP and incubated

about 20° to about 65° C., more preferably from about 40°
to about 45° C. are used.

The sample may be equilibrated to room temperature
before removing the solvent or the solvent may be removed

FIG. 2 shoWs that the yield of spin adduct Was at least
tripled after TFE treatment upon a double integration of the

FIG. 3 shoWs the results of GS toxicity assays performed

Then, the dissolved oligopeptide or polypeptide is
incubated, for example, in glass vials, for a period of time
ranging from about 30 minutes to about 4 hours, preferably

suitable temperature. Preferably temperatures ranging from

FIG. 1 shoWs the PBN spin adducts formed by

spectra;

The oligopeptide or polypeptide is dissolved in the sol
vent to an appropriate concentration ranging from about
0.01 to 10 mg/ml, preferably from about 0.1 to 5 mg/ml, and
more preferably from about 0.15 to 1.0 mg/ml.

from about 45 minutes to 3 hours, more preferably from
about 1 hour to about 2 hours.
During incubation the samples are gently heated to any

BRIEF DESCRIPTION OF THE DRAWINGS

co-incubation of A[3(1-40) (SEQ ID NO:8) before and after
the TFE-restructuring process;

Before pre-treatment of the oligopeptide or polypeptide
With the solvent and/or before dissolving the oligopeptide or
polypeptide in the solvent, the solvent may be deoxygenated

minutes to about 10 minutes.
55

in PBS for 24 hours in the presence and absence of 50 mM

PBN; and

The present invention also provides novel oligopeptides
and polypeptides enhanced by the process according the
invention.

FIGS. 5A—5D shoW the EPR spectra of PBN spin adducts
formed from A[3(25-35) before and after TFE- or DMSO
treatment.

The folloWing examples are merely illustrative of the
60

examples and other equivalents Will become more apparent
to those skilled in the art in light of the present disclosure.

DETAILED DESCRIPTION OF THE
INVENTION

EXAMPLE 1

The present invention provide a novel process for enhanc

ing activity of an oligopeptide or polypeptide comprising the
steps of: providing an oligopeptide or polypeptide, dissolv
ing the oligopeptide or polypeptide in an organic solvent,

present invention and they should not be considered as
limiting the scope of the invention in any Way, as these

65

Solvation Activation Process

Tri?uoroethanol (TFE) (Aldrich Chemical, MilWaukee,
Wis.) Was initially thoroughly degassed by N2 sparge.

5,840,838
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Samples of synthetic amyloid beta peptide, A[3(1-40) (SEQ

loid beta peptide (1 mg/ml) Was incubated With phenyl-tert

butylnitrone [50 mM PBN (Centaur Pharmaceuticals,

ID NO:8) [Bachem lot ZM094], Were divided into TFE
treated and control samples. TFE-treated samples Were
dissolved in deoxygenated TFE to a concentration of 0.15

Sunnyvale, Calif.) in 5 mM K2HPO4/KH2PO4+5 mM NaCl
pH 7.0] at 37° C. for 1—24 hours, then analyZed by EPR

mg/ml and incubated in glass vials for 2 hours at 40°—45° C.
The TFE/AB solution Was initially cloudy but became clear

(incident poWer=19 mW, incident frequency=9.76 GHZ,

after about 1 hour at 40° C. The TFE/AB solutions Were
equilibrated to room temperature folloWed by removal of the
TFE by rapid evaporation under a stream of N2 gas.

versiton time=10.28 mS).
Reactive amyloid beta produces stable free radical

EXAMPLE 2

spectrometry using a Bruker 300 EPR spectrometer

modulation amplitude=0.9 G, time constant=1.28 mS, con

10

Peptide Toxicity Assessed By Glutamine Synthetase
Inactivation

Glutamine synthetase (GS) Was assayed in brain cortical

homogenate prepared from male mongolian gerbils
(Tumblebrook Farms, W. Brook?eld, Mass.). Amyloid beta

15

titatively similar, the TFE-treated sample produced a sig
ni?cantly greater yield of spin-adduct and double integration
of the spectra shoWed that the yield of spin adduct Was at
20

concentration 1 mg/ml). After 3 hours incubation at 37° C.

Peptide Aggregation Assessment by Electron
25

hours at 37° C. in phosphate buffer :50 mM PBN. 20 uL

aliquots of the peptide incubate Were evaporated to dryness
on silicon grids and counterstained With uranyl acetate.

1418—1422 (1978) and corrected for nonspeci?c glutami

Electron microscopy Was performed on a Hitachi 7000

nase activity by comparison in the presence and absence of

transmission electron microscope operating at 75 KV.
FIG. 4 shoWs electron micrographs of A[3(1-40) (SEQ ID
N018) before and after TFE-SARP and incubated in PBS for

ADP and arsenate.

24 hours in the presence and absence of 50 mM PBN. These
35

inevitably lost (even in the absence of added peptide) due to
spontaneous oxidation of the sensitive enZyme. The activity
of the enZyme decreases by approximately 30% after 3 hours

formed visible ?brils upon incubation in the buffer. Native,
unmodi?ed AB coincubated With PBN demonstrated both
?brils and an amorphous component Which stains more
40

deposits and regions of dark amorphous staining. In the
presence of PBN, the ?bril density appeared someWhat

?ed A[3(1-40) (SEQ ID NO:8) (Bachem lot ZM094), GS
activity decreases approximately 45% relative to its initial
activity. Thus, the peptide appears to have some toxic
potential, but signi?cantly less than has been previously
reported With regard to the A[3(1-40) (SEQ ID NO:8) or the

greater than in PBN absence; the circular components Were
smaller and sparcer; and lightly stained intra?brillar material
Was seen in the PBN-coincubated, native AB samples.
50

GS activity after 3 hours coincubation. These samples lost

increase in toxicity of the native, unmodi?ed AB correlating
55

In all cases, inclusion of 50 mM PBN in the GS incubate

inhibited spontaneous GS oxidation and also A[3-mediated

loss in GS activity (FIG. 3). BetWeen the PBN/AB
containing samples, GS activity shoWed a 3-fold greater
decrease in the presence of TFE-pretreated AB than in the

different reactivity than the native peptide, producing a
60

tides more toxic than 4-line generating variants. The DMSO

EXAMPLE 3

electron paramagnetic resonance (EPR) spin trapping. Amy

3-line EPR spectrum rather than a 4-line spectrum. Previous

data shoWed a strong correlation betWeen peptide toxicity
and PBN spin adduct spectra, With 3-line generating pep

tion to EPR results obtained from these treatments.

Amyloid beta free radical generation Was assessed by

[Bachem lot WL650] Was modi?ed by TFE- and DMSO
treatment of the original peptide lyophilate. FIG. 5 shoWs
the EPR spectra of PBN spin adducts formed from A[3(25
25) (SEQ ID NO:5) before and after TFE- or DMSO
treatment. The TFE-treated peptide shoWed a qualitatively

presence of native, unmodi?ed AB , again in close correla

Peptide Free Radical Generating Capacity

EXAMPLE 5

Activation of A[3(25-35) (SEQ ID NO:5)
The reactivity of loW-activity A[3(25-35) (SEQ ID NO:5)

over 90% of initial GS activity. This represents a 3-fold

With the EPR spin trapping results described herein.

lightly and spans the inter?brillar regions. TFE-AB treat
ments differed dramatically in morphology from the native,
unmodi?ed peptide. TFE-treated AB formed very feW ?brils,
and along the ?bril tracks Were numerous circular or oblong

incubation in the absence of AB. In the presence of unmodi

toxic A[3(25-35) (SEQ ID NO:5) sequences. TFE-treated
A[3(1-40) (SEQ ID NO:8) engenders a much greater loss in

also represent aliquots of samples used in the EPR and

enZyme activity investigations. The native, unmodi?ed AB

in parallel With, and using aliquots of the sample peptide
preparations. The GS activity in this experiment is expressed
relative to the initial GS activity of brain extract before
incubation at 37° C., during Which some GS activity is

Microscopy
Amyloid beta peptide Was preincubated at 1 mg/ml for 24

method of RoWe et al., Glutamine Synthetase, Methods
EnZymol. 17 NeW York: Academic Press, 1970: 900—910; as
modi?ed by Miller et al., Proc. Natl. Acad. Sci. USA 75,

Toxic AB inactivates the oxidation-sensitive enZyme
glutamine synthetase (GS) in vitro, and this measure of
toxicity is used to index relative reactivity of AB samples.
FIG. 3 illustrates the results of GS toxicity assays performed

least tripled after TFE treatment (FIG. 2).
EXAMPLE 4

(brain protein concentration in incubate=0.2 mg/ml, peptide
in phosphate buffer, aliquots of GS/peptide co-incubate Were
removed and assayed for GS activity by the calorimetric

PEN spin adducts formed by conincubation of A[3(1-40)
(SEQ ID NO:8) [Bachem lot ZM094] before and after the
TFE-restructuring process. Although, the spectra are quan

peptide Was tested for its ability to inactivate GS by ?rst

preincubating the peptide for 24 hours in phosphate buffer (1
mg/ml concentration, 5 mM K2HPO4/KH2PO4+5 mM NaCl
pH 7.0) then co-incubating the peptide solution With brain
cytosolic extract prepared from gerbil cortical homogenates

adducts of PBN Which are detectable and quanti?able by
EPR. The type and quantity of PBN adduct produced upon
reaction with A6 correlates With the degree of GS toxicity or
cytotoxicity inherent in the AB sample. FIG. 1 shoWs the

treated peptide demonstrated both the 4-line component and
65

a nascent but Weak 3-line component. Control experiments
using H2O in place of the organic solvent had no effect on
the nature of the PBN spin adduct.

5,840,838
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EXAMPLE 6

of the peptide lyophilate. By separating and unfolding small
polymolecular aggregates in the lyophilate and thereby
freeing previously concealed reactive peptide radicaliZation

Morphology of Aggregate Structures

sites, the present process signi?cantly enhances the reactiv

Toxic AB has a very facile ?bril-forming capacity,

ity of synthetic peptides, including synthetic AB peptides.

Whereas loW-activity samples of AB form small amorphous
or unstructured aggregates. The type of aggregate or poly
mer formed in the AB may re?ect the initial aggregate
condition of reactive polymolecular structures present in the

peptide lyophilate prior to solubiliZation, and hence should
be effected by protocols designed to modulate peptide

DETAILED DESCRIPTION OF THE DRAWINGS

FIG. 1: PBN spin adduct EPR spectra obtained from
10

structure and toxicity. FIG. 5 shoWs electron micrographic
evidence that TFE treatment dramatically modi?ed peptide

hours incubation in phosphate buffer (FIG. 5A). TFE-treated
peptide formed only sparse ?brils, along Which are located

FIG. 2: Double integrated intensity (arbitrary units) of

40) (SEQ ID NO.8) samples;
15

(SEQ ID NO:8) incubated at 1 mg/ml for 24 hours at 37° C.
in PBS pH 7.0; holloW bars indicate samples that also

(FIG. 5B). This Was the case in both PBN-free and PBN

contained 50 mM PBN. After the 24 hour incubation period,
the peptide samples Were coincubated With brain extract (1

coincubated, TFE-treated A[3(1-40) (SEQ ID NO:8). In the
PBN-treated samples, ?bril density Was slightly greater, and

mg/ml peptide, 0.2 mg/ml brain extract) for 3 hours prior to

the spherical inclusions Were smaller and feWer. In the PBN

GS assay. Data are represented as % loss of GS activity
relative to GS samples that Were not subjected to 3 hours of

coincubated samples (both native and TFE-treated peptide),
there Were lightly stained deposits spanning the inter?brillar

regions (FIG. 5 CD). In control experiments Where the PBN

FIG. 3: GS inactivation by native and TFE-treated A[3(1

40) (SEQ ID NO:8). Solid bars indicate samples of A[3(1-40)

circular or spherical structures and opaquely-stained regions

Was added after the 24 hour peptide preincubation period

(loWer) TFE-treatment as described in the text;

EPR signals corresponding to TFE-treated or native A[3(1

?brillogenic potential. The slightly toxic, native peptide
formed a moderately dense netWork of ?laments after 24

synthetic A[3(1-40) (SEQ ID NO:8) before (upper) and after

37° C. incubation;
25

FIG. 4: Electron micrographs ofA[3(1-40) (SEQ ID NO:8)
after 24 hours incubation in phosphate. A: Native, untreated

(i.e., after ?brillogenesis), these highly stained deposits Were
not visible. Therefore, the lightly-stained PBN-derived

peptide. B: TFE-treated peptide. C: Native peptide coincu

structure represents a feature of PBN/AB interaction rather
than simply a result of PBN precipitation.
EPR spectroscopy, enZyme assay, and electron micros
copy have demonstrated a dramatic modi?cation in reactiv

bated With 50 mM PBN. D: TFE-treated peptide coincubated
With 50 mM PBN; and
FIG. 5: PBN spin adduct EPR spectra obtained from

30

synthetic A[3(25-35) (SEQ ID NO:5) (lot WL650) treated by
various solvation procedures prior to coincubation of pep
tide lyophilate With PBN. A: native, unmodi?ed peptide. B:

ity of synthetic A[3(1-40) (SEQ ID NO:8) upon treatment
With the process of the present invention. The 3-fold
increase in EPR signal intensity and GS inactivation upon

35

Peptide dissolved in H20 and relyophiliZed prior to spin
trapping. C: Peptide dissolved in DMSO and relyophiliZed

TFE treatment, along With the observation that GS activity
is protected by PBN inclusion, shoWs that the oxidative

prior to spin trapping. ArroWs indicate nascent 3-line com

potential of the AB peptide is markedly increased by TFE
mediated unfolding and subsequent refolding of the peptide.

ponent. D: Peptide dissolved in TFE and N2 evaporated prior
to spin trapping.

The electron microscopic data clearly indicate a difference
in aggregation behavior betWeen native and TFE-treated AB.
While not Wishing to be bound by any particular theory,
it is possible that lot-to-lot variations in potency among

synthetic AB peptides stem from alternate positioning of
reactive radicaliZation sites Within polymolecular aggregates

40

The purpose of the above description and examples is to
illustrate some embodiments of the present invention With
out implying any limitation. It Will be apparent to those of
skill in the art that various modi?cations and variations may

be made to the present invention Without departing from the
spirit or scope of the invention.

SEQUENCE LISTING

( 1 ) GENERAL INFORMATION:
( i i i )NUMBER OF SEQUENCES: 11

( 2 ) INFORMATION FOR SEQ ID NO:1:

( i )SEQUENCE CHARACTERISTICS:
( A ) LENGTH: 15 amino acids
( B )TYPE: amino acid

( c ) STRANDEDNESS: single
( D )TOPOLOGY: linear
( i i )MOLECULE TYPE: peptide
( X i )SEQUENCE DESCRIPTION: SEQ ID N0:1:

Asp
1

Ala

Glu

Phe

Arg
5

His

Asp

Se

Gly

Tyr
10

Glu

Val

His

His

Gln
15

5,840,838
-c0ntinned
( 2 ) INFORMATION FOR SEQ ID NO:2:

( i )SEQUENCE CHARACTERISTICS:
( A ) LENGTH: 28 amino acids
( B )TYPE: amino acid

( c )STRANDEDNESS: single
( D )TOPOLOGY: iiiieai
( i i ) MOLECULE TYPE: peptide
( X i ) SEQUENCE DESCRIPTION: SEQ ID NO:2:

Asp

Ala

Gln

Phe

1

Len

Arg

His

Asp

Ser

Gly

5

Val

Phe

Phe

Ala

Tyr

Gln

Val

His

His

1O

Gln

Asp

Val

2 O

Gly

Gln

Lys

15

Ser

Asn

Lys

Tyr

Gln

Val

2 5

( 2 ) INFORMATION FOR SEQ ID NO:3:

( i )SEQUENCE CHARACTERISTICS:
( A ) LENGTH: 30 amino acids
( B )TYPE: amino acid

( C ) STRANDEDNESS: single
( D )TOPOLOGY: linear
( i i )MOLECULE TYPE: peptide
( X i ) SEQUENCE DESCRIPTION: SEQ ID NO:3:

Asp

Ala

Gln

Phe

1

Len

Arg

His

Asp

Ser

Gly

5

Val

Phe

Phe

Ala

His

His

1O

Gln

Asp

Val

2 O

Gly

Ser

Gln

Lys

15

Asn

Lys

Gly

2 5

Ala
3 O

( 2 ) INFORMATION FOR SEQ ID NO:4:

( i )SEQUENCE CHARACTERISTICS:
( A ) LENGTH: 33 amino acids
( B )TYPE: amino acid

( C ) STRANDEDNESS: single
( D )TOPOLOGY: linear
( i i )MOLECULE TYPE: peptide
( X i ) SEQUENCE DESCRIPTION: SEQ ID NO:4:

Asp

Ala

Gln

Phe

1

Len

Arg

His

Asp

Ser

Gly

5

Val

Phe

Phe

Ala

Tyr

Gln

Gln

Asp

Val

2O

Gly

Ser

Asn

25

( i )SEQUENCE CHARACTERISTICS:
( A ) LENGTH: 11 amino acids
( B )TYPE: amino acid

( C ) STRANDEDNESS: single
( D )TOPOLOGY: linear
( i i )MOLECULE TYPE: peptide
( X i ) SEQUENCE DESCRIPTION: SEQ ID NO:5:

Ser

Asn

Lys

Gly
5

( 2 ) INFORMATION FOR SEQ ID NO:6:

( i )SEQUENCE CHARACTERISTICS:
( A ) LENGTH: 36 amino acids

His

Ala

Ile

Ile

Gly

Lys

Gly

Ala
3O

( 2 ) INFORMATION FOR SEQ ID NO:5:

1

His

Len
1 O

Gln

Lys

15

Gly

Gly

Val

1O

Met

Ile

Ile

5,840,838
11

12
-continued

( B )TYPE: amino acid

( C ) STRANDEDNESS: single
( D )TOPOLOGY: linear
( i i )MOLECULE TYPE: peptide
( X i ) SEQUENCE DESCRIPTION: SEQ ID NO:6:

Asp

Ala

Glu

Phe

1

Leu

Arg

His

Asp

Ser

Val

Phe

Phe

Ala

Leu

Met

Tyr

Glu

Val

His

His

1O

Glu

Asp

Val

2O

Gly

Gly

5

Gly

Ser

Gln

Lys

15

Asn

Lys

Gly

25

Ala

Ile

Ile

Gln

Lys

3O

Val

35

( 2 ) INFORMATION FOR SEQ ID NO:7:

( i )SEQUENCE CHARACTERISTICS:
( A ) LENGTH: 39 amino acids
( B )TYPE: amino acid

( C ) STRANDEDNESS: single
( D )TOPOLOGY: linear
( i i )MOLECULE TYPE: peptide
( X i ) SEQUENCE DESCRIPTION: SEQ ID NO:7:

Asp

Ala

Glu

Phe

1

Leu

Arg

His

Asp

Ser

Val

Phe

Phe

Ala

Leu

Met

Tyr

Glu

Val

His

Glu

Asp

Val

Gly

Ser

15

Asn

Lys

Gly

25

ValGly

His

1O

2O

Gly

Gly

5

Gly

Ala

Ile

Ile

Gln

Lys

3O

Val

35

( 2 ) INFORMATION FOR SEQ ID NO:8:

( i )SEQUENCE CHARACTERISTICS:
( A ) LENGTH: 40 amino acids
( B )TYPE: amino acid

( C ) STRANDEDNESS: single
( D )TOPOLOGY: linear
( i i )MOLECULE TYPE: peptide
( X i ) SEQUENCE DESCRIPTION: SEQ ID NO:8:

Asp

Ala

Glu

Phe

1

Leu

Arg

His

Asp

Ser

Val

Phe

Phe

Ala

Leu

Met

Tyr

Glu

Val

His

Glu

Asp

Val

Gly

Ser

15

Asn

Lys

Gly

25

ValGly

His

1O

2O

Gly

Gly

5

Gly

Ala

Ile

Ile

Gln

Lys

3O

ValVal

35

4O

( 2 ) INFORMATION FOR SEQ ID NO:9:

( i )SEQUENCE CHARACTERISTICS:
( A ) LENGTH: 42 amino acids
( B )TYPE: amino acid

( C ) STRANDEDNESS: single
( D )TOPOLOGY: linear
"
11

MOLECULETYPE :et1e
pp'd

( X i ) SEQUENCE DESCRIPTION: SEQ ID NO:9:

Asp

Ala

Glu

Phe

1

Leu

Arg

His

Asp

Ser

Gly

5

Val

Phe

Phe
2O

Ala

Tyr

Glu

Val

His

His

1O

Glu

Asp

Val

Gly
25

Ser

15

Asn

Lys

Gly

Ala
3O

Ile

Ile

5,840,838
-continued
Gly

Len

Met

ValGly

Gly

ValVal

35

Ile

Ala

Gly

Tyr

40

( 2 ) INFORMATION FOR SEQ ID NO:10:

( i )SEQUENCE CHARACTERISTICS:
( A ) LENGTH: 47 amino acids
( B )TYPE: amino acid

( C ) STRANDEDNESS: single
( D )TOPOLOGY: linear
( i i )MOLECULE TYPE: peptide
( x i ) SEQUENCE DESCRIPTION: SEQ ID NO:10:

Asp

Ala

Gln

Phe

1

Len

Arg

His

Asp

Ser

5

Val

Phe

Phe

Ala

Gln

Asp

Val

20

Gly

Len

Met

Gln

Val

His

His

10

Gly

Ser

ValGly

Gly

ValVal

Lys

15

Asn

Lys

Gly

Ala

25

35

Gln

Ile

Ile

30

Ile

Ala

Thr

Val

Ile

40

Val

Ile

His

Gln

45

( 2 ) INFORMATION FOR SEQ ID NO:11:

( i )SEQUENCE CHARACTERISTICS:
( A ) LENGTH: 52 amino acids
( B )TYPE: amino acid

( C ) STRANDEDNESS: single
( D )TOPOLOGY: linear
( i i )MOLECULE TYPE: peptide
( x i ) SEQUENCE DESCRIPTION: SEQ ID NO:11:

Asp

Ala

Gln

Phe

1

Len

Arg

His

Asp

Ser

Val

Phe

Phe

Ala

Len

Met

ValGly

Gln

Val
50

Met

Gln

Val

His

Asp

Val

Gly

Ser

Gly

ValVal

Lys

15

Asn

Lys

Gly

Ala

25

35
Len

Tyr
10

20

Gly

Gly

5

Ile

Ile

Ile

Thr

30

Ile

Ala

Thr

Val

Ile

40

Val

45

Len

We claim:

4. The process of claim 1, Wherein the peptide recovered
in step e) shoWs sparse ?brils along Which are located
circular or spherical structures and opaquely stained regions

1. Aprocess for treating a synthetic amyloid beta peptide,
Which process comprising the steps of:

in an electron micrograph.

a) providing a synthetic amyloid beta peptide;
b) dissolving the synthetic amyloid beta peptide in a

5. The process of claim 1, Wherein the synthetic amyloid
beta peptide is selected from group consisting of A[3(1-15),

deoXygenated solvent selected from the group consist

A[3(1-28), A[3(1-30), A[3(1-33), A[3(25-35), A[3(1-36), A[3(1
39), A[3(1-40), A[3(1-42), A[3(1-47), and A[3(1-52).

ing of tri?uoroethanol, dimethyl sulfoXide,

heXa?uorocycloheXane, morpholino-propanesulfonic

6. The process of claim 1, Wherein the deoXygenated

acid, dimethylformamide, and acetonitrile to a concen

solvent is deoXygenated by N2 sparge.

tration ranging from about 0.01 to about 10 mg/ml;

c) incubating the dissolved synthetic amyloid beta peptide

7. The process of claim 1, Wherein the synthetic amyloid

for about 30 minutes to about 4 hours at a temperature

beta is dissolved in the deoXygenated solvent to a concen

betWeen about 20° C. to about 65° C.;

tration of about 0.1 to about 5 mg/ml.

d) removing the solvent by evaporative deposition in

8. The process of claim 7, Wherein the synthetic amyloid

about 5 to about 10 minutes; and

beta peptide is dissolved in the deoXygenated solvent to a
concentration of about 0.15 to about 1.0 mg/ml.
9. The process of claim 1, Wherein the incubating step is

e) recovering the synthetic amyloid beta peptide obtained
in step d.
2. The process of claim 1, Wherein the peptide recovered
in step e) produces a three-line or four-line EPR(electron

aO

carried out at a temperature betWeen about 40° C. to about

45° C.
10. A process according to claim 1, Wherein the incubat
paramagnetic resonance) spectrum upon reaction With PBN
ing step is carried out for about 45 minutes to about 3 hours.
(phenyl-tert-butylnitrone) With an increased integrated
11. A process according to claim 10, Wherein the incu
intensity relative to the provided peptide.
3. The process of claim 1, Wherein the peptide recovered m 5 bating step is carried out for about 1 hour to about 2 hours.

in step e) leads to greater loss of GS(glutamine synthetase)
activity than the provided peptide.

*

*

*

*

*

